Excerpt from original article, "NIH consortium takes aim at vascular disease-linked cognitive impairment and dementia," posted on NIH News Releases, February 27, 2017.
To better predict, study, and diagnose small vessel disease in the brain and its role in vascular contributions to cognitive impairment and dementia (VCID), the National Institutes of Health has launched MarkVCID, a consortium designed to accelerate the development of new and existing biomarkers for small vessel VCID.
The five-year program, developed by the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), in collaboration with the National Institute on Aging (NIA), consists of seven research groups across the United States working together via a coordinating center based at Massachusetts General Hospital, Boston. A kick-off meeting for the consortium was held immediately prior to the International Stroke Conference 2017 in Houston, Feb. 20-21.
Steven M. Greenberg, M.D., Ph.D., director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital will serve as the project leader for the MarkVCID Coordinating Center.
“We have brought together a number of outstanding research groups to further develop and validate candidate biomarkers for cerebral small vessel disease,” said Dr. Greenberg. “This will be achieved by identifying and focusing on the most promising biomarkers across the research sites.”